NEW YORK, USA; and MELBOURNE, Australia, July 25, 2019 -- Cardiovascular journal Circulation Research has published a special article highlighting the potential clinical benefits of an allogeneic mesenchymal precursor cell
(MPC) technology as immunotherapy in patients with advanced chronic heart failure, Mesoblast Limited (NASDAQ: MESO) announced.
and covers a method for generating therapeutic precursor cell
products, including the company's lead product ACP-01.
Mesoblast announced that enrollment has completed in the Phase 3 trial evaluating a single intra-discal injection of its proprietary allogeneic mesenchymal precursor cell
product candidate MPC-06-ID in patients with chronic low back pain due to degenerative disc disease.
The benefits derived from acquiring the approved and late-phase MSC products include: *near term launch of a mesenchymal lineage product in major jurisdictions; *broadened late -phase clinical programs in strategic areas of focus; and *leveraged roll out of infrastructure, skills and expertise needed to commercialize Mesenchymal Precursor Cell
(MPC) products Mesoblast said.
Japanese patent number 5265190 provides Mesoblast with exclusive commercial rights in Japan through to September 2025 to all compositions-of-matter and uses of its Mesenchymal Precursor Cell
(MPC)technology platform, irrespective of the MPC tissue source, including bone marrow, adipose, placenta, umbilical cord and dental pulp.
Mesoblast's off-the-shelf, allogeneic, Mesenchymal Precursor Cell
(MPC) product for Type 2 diabetes is the first of the company's suite of biologic therapies to be delivered via a simple intravenous injection.
Working in the laboratory, the scientists found that in the absence of Wnt-10b both types of mouse precursor cell
turned into fat.
Scharfman et al., "Neuropeptide Y is important for basal and seizure-induced precursor cell
proliferation in the hippocampus," Neurobiology of Disease, vol.
Melbourne, Australia, Nov 22, 2011 - (ABN Newswire) - Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the key elements of the company's first clinical trial using intravenous delivery of its proprietary allogeneic, or off-the-shelf, mesenchymal precursor cell
(MPC) technology in patients with Type 2 Diabetes.
In Alexander disease, a mutation in glial cells called astrocytes inhibits a type of precursor cell
that later becomes myelin, the fatty sheath that facilitates communication within the brain's network.
The clinical trial will focus on the company's off-the-shelf, allogeneic, Mesenchymal Precursor Cell
(MPC) product for Type 2 diabetes, which is the first of Mesoblast's suite of biologic therapies to be delivered via intravenous injection.
I propose to replenish the tissue-specific precursor cell
pool by directly programming local somatic cell types into relevant precursors.